@article{3e3964a3f9c84929b329d818f3f2a238,
title = "Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies",
abstract = "Background: Myelitis accompanied by a negative spinal cord MRI may lead to diagnostic uncertainty. Objective and Methods: We retrospectively investigated the frequency of negative spinal cord MRI (performed <6 weeks from onset) in Mayo Clinic patients with myelin oligodendrocyte glycoprotein (MOG)-IgG-associated myelitis (2000–2019). Results: The initial spinal cord MRI was negative in 7/73 (10%) patients, despite severe acute disability (median EDSS, 7 (range, 4.5–8)); myelitis symptoms/signs were frequent (paraparesis, neurogenic bladder, sensory level, Lhermitte{\textquoteright}s phenomenon). Myelitis lesions became overt at follow-up MRI in three patients. Conclusions: A negative spinal cord MRI should not dissuade from MOG-IgG testing in patients with acute/subacute myelitis.",
keywords = "Demyelination, MRI, T2 lesions, acute transverse myelitis, myelin oligodendrocyte glycoprotein, neuromyelitis optica",
author = "Elia Sechi and Krecke, {Karl N.} and Pittock, {Sean J.} and Divyanshu Dubey and Lopez-Chiriboga, {A. Sebastian} and Amy Kunchok and Weinshenker, {Brian G.} and Zalewski, {Nicholas L.} and Flanagan, {Eoin P.}",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.J.P. reports grants, personal fees, non-financial support, and other from Alexion Pharmaceuticals, Inc.; grants from Grifols; other from Euroimmun; grants from National Institutes of Health (NIH); grants, personal fees, and non-financial support from Guthy-Jackson Charitable Foundation; grants from AEA (Autoimmune Encephalitis Alliance); and grants, personal fees, non-financial support, and other from MedImmune, Inc.; in addition, he has a patent (patent #8889102) (application#12-678350) on neuromyelitis optica autoantibodies as a marker for neoplasia, and also a patent (patent #9891219B2) (application#12-573942) on methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive; patents on GFAP-IgG, Septin-5-IgG, MAP1B-IgG, Kelch-like protein 11, and PDE10A are all pending. B.G.W. receives royalties from RSR Ltd, Oxford University, Hospices Civil de Lyon, and MVZ Labor PD Dr. Volkmann und Kollegen GbR for a patent of NMO-IgG as a diagnostic test for NMO and related disorders. He serves as a member of an adjudication committee for clinical trials in NMO being conducted by VielaBio and Alexion pharmaceutical companies. He is a consultant for Chugai Pharma and Mitsubishi Tanabe regarding potential clinical trials for NMO. E.P.F. receives research support as a site principal investigator in a randomized placebo-controlled clinical trial of inebilizumab (a CD19 inhibitor) in neuromyelitis optica spectrum disorders funded by MedImmune/Viela Bio. E.S., K.N.K., D.D., A.S.L., A.K., and N.L.Z. have nothing to disclose. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: We would like to acknowledge funding support from the NIH National Institute of Neurological Disorders and Stroke (R01NS113828). This study was also supported by the Guthy-Jackson Charitable Foundation and the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology that provided support through a translational clinical fellowship grant. ",
year = "2021",
month = feb,
doi = "10.1177/1352458520907900",
language = "English (US)",
volume = "27",
pages = "303--308",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "2",
}